- Home
- AWP vs PHAT Comparison
AWP vs PHAT Comparison
Compare AWP & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AWP | PHAT |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.9M | 942.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | AWP | PHAT |
|---|---|---|
| Price | $3.84 | $14.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.33 |
| AVG Volume (30 Days) | 331.5K | ★ 777.9K |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 12.48% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $147,190,000.00 |
| Revenue This Year | N/A | $218.59 |
| Revenue Next Year | N/A | $84.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 460.30 |
| 52 Week Low | $3.06 | $2.21 |
| 52 Week High | $4.20 | $16.45 |
Technical Indicators
Market Signals| Indicator | AWP | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 43.79 | 53.40 |
| Support Level | $3.81 | $14.12 |
| Resistance Level | $3.98 | $16.27 |
| Average True Range (ATR) | 0.05 | 0.74 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 26.47 | 23.18 |
Price Performance
Historical ComparisonAbout AWP abrdn Global Premier Properties Fund of Beneficial Interest
Aberdeen Global Premier Properties Fund is a diversified, closed-end management investment company. Its objective is to seek high current income and capital appreciation. It predominantly invests in equity and debt securities of domestic and foreign issuers which are principally engaged in the real estate industry, real estate financing or control real estate assets. Its portfolio of investments consists securities of Industrial REITs, Retail REITs, Data Center REITs, Health Care REITs and others.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.